What Is Toradol Used For? ER Pain, Dosage, and Safety

Toradol is the brand name for ketorolac tromethamine, a powerful nonsteroidal anti-inflammatory drug (NSAID) used to treat moderate to severe pain on a short-term basis. Unlike many common pain relievers you can buy at the pharmacy, Toradol is most often given by injection or intravenously in hospitals and emergency departments, though oral tablets and even eye drops exist. Its reputation rests on a somewhat unusual combination: it can relieve pain at a level closer to opioids while carrying none of the sedation, addiction risk, or respiratory depression that come with narcotics.

Where Toradol Gets Used Most

Toradol is one of the go-to nonopioid options for treating acute pain in emergency departments and surgical recovery rooms. It is classified as a commonly used parenteral analgesic for ED patients presenting with acute pain, and it shows up in settings ranging from kidney stone attacks and broken bones to post-surgical recovery and severe headaches.¹ Clinicians reach for it when they need fast, strong pain control but want to avoid the downsides of morphine or similar opioids. It is not meant for chronic conditions like arthritis or back pain that lingers for weeks. Its approved use is strictly short-term, and there is a hard ceiling on how long you should take it, which we will get to below.

The drug works the same way other NSAIDs do, by blocking enzymes involved in producing prostaglandins, the chemicals that drive pain, inflammation, and fever. What sets ketorolac apart from ibuprofen or naproxen is potency: milligram for milligram, it hits much harder. A systematic review of randomized trials found that ketorolac reduced the need for opioid painkillers by an average of about 36% after surgery, with reductions ranging from near zero in some procedures to as high as 73% in others.² That opioid-sparing quality is the main reason Toradol has carved out such a strong niche in acute-care medicine.

How It Is Given

Toradol comes in several forms, and the route of delivery shapes how quickly it works and who it is best suited for.

Intramuscular injection: A shot into the muscle, usually the thigh or buttock. This is the classic “Toradol shot” many people receive in the ER or after surgery. Onset is fairly quick, with peak drug levels reached within about an hour.
Intravenous (IV): Pushed directly into a vein, this works the fastest and is common during or immediately after surgical procedures.
Intranasal spray: A newer delivery option. Studies show the nasal spray is rapidly absorbed, reaching peak levels in about 30 to 45 minutes, with a half-life of roughly five to six hours, similar to the injected form. The nasal route delivers about 67% to 75% of the drug compared to an equivalent intramuscular dose.³
Oral tablets: Available for short-term follow-up after injectable treatment, though oral Toradol is prescribed far less frequently than the injectable forms.
Ophthalmic drops: A separate formulation used in eye care, discussed further below.

The injectable and IV forms are the workhorses. Most patients encounter Toradol when a nurse or doctor administers it during an acute pain episode, not as something they pick up at a pharmacy and take at home.

Kidney Stones and Emergency Pain

If you have ever had a kidney stone, you know it produces some of the worst pain a person can experience without a surgical wound. Toradol is a standard part of the emergency toolkit for renal colic. A meta-analysis of randomized trials found that adding ketorolac to the treatment plan for kidney stone pain produced significantly lower pain scores within the first 10 to 20 minutes and cut the need for additional rescue painkillers by about a third.⁴ A randomized trial comparing three different IV ketorolac doses for kidney stones found that all three brought substantial pain relief within 30 minutes, with no significant differences between the 10, 20, and 30 mg arms.⁵

A separate trial comparing morphine combined with ketorolac against morphine alone found that the combination group had dramatically lower pain scores by two hours. Patients receiving morphine plus ketorolac had average pain ratings around 2.9 out of 10 at the two-hour mark, while those on morphine alone were still at 7.0.⁶ That gap is hard to ignore, and it helps explain why ketorolac is so popular in emergency medicine for this condition.

Migraine Treatment in the ER

Toradol is also widely used for acute migraine attacks that land people in the emergency department. A systematic review of the evidence found that ketorolac is an effective alternative for migraine relief, performing comparably to the opioid meperidine (Demerol) and outperforming the triptan sumatriptan. The review did note that ketorolac may not be quite as effective as dopamine-blocking agents like metoclopramide or phenothiazines, which some ERs use as first-line migraine treatments.⁷ Still, the fact that Toradol relieves migraine pain without the sedation and nausea that opioids bring makes it a practical choice, especially when patients need to function afterward.

Postoperative Pain and Reducing Opioid Use

This is arguably where Toradol has had its biggest impact. Surgeons and anesthesiologists use it as part of what is called multimodal analgesia, combining several different types of pain relief so that no single drug has to do all the heavy lifting. The payoff is that patients need less morphine, hydrocodone, or oxycodone after their procedure, which means fewer opioid side effects like nausea, constipation, excessive sedation, and the potential for dependence.

A meta-analysis focused on lumbar spine surgery found that ketorolac significantly reduced both pain scores and postoperative opioid consumption, with no significant increase in adverse effects.⁸ A broader review of its postoperative safety profile concluded that ketorolac is safe and effective in healthy surgical patients and is “particularly beneficial as an opioid-sparing agent in vulnerable patient groups.”⁹ After total knee replacement, a randomized trial found that patient-controlled analgesia built around ketorolac (combined with another non-opioid) provided pain relief that was no worse than traditional opioid-based regimens, while cutting opioid consumption and reducing drug-related side effects.¹⁰

Given the ongoing opioid crisis, this capacity to deliver strong pain relief while minimizing narcotic exposure is a big deal. It is one of the main reasons Toradol remains so widely used despite its own set of risks.

The Ophthalmic Version

A separate formulation of ketorolac exists as a 0.5% eye drop solution, and it serves a completely different purpose from the injectable form. Ophthalmologists prescribe it to control inflammation and pain after eye surgery, particularly cataract procedures. A randomized trial showed that ketorolac eye drops provided substantial anti-inflammatory effect in patients who developed moderate to severe inflammation after cataract surgery and lens implantation.¹¹ The drops are also used to manage seasonal allergic conjunctivitis, where they reduce itching and redness. This is a niche use that most people never hear about, but it is worth knowing that the “Toradol” name on an eye drop bottle is the same underlying drug.

How It Compares to IV Acetaminophen

With hospitals increasingly stocking IV acetaminophen (Ofirmev), a natural question is how it stacks up against ketorolac for acute pain. The evidence suggests they perform similarly overall, though ketorolac may have an edge for severe pain. A retrospective study of over 2,100 prehospital patients found no statistically significant difference in pain score change between IV acetaminophen and parenteral ketorolac across all patients, including those with traumatic injuries.¹² A randomized trial in prehospital emergency services reached a similar conclusion overall, but noted that ketorolac was more effective at reducing pain scores in patients with severe pain specifically.¹³ For mild to moderate pain, either drug appears to work about equally well. For more intense pain, ketorolac likely has the advantage.

Does the Dose Really Matter?

Historically, the standard IV or IM dose of ketorolac was 30 mg (or 60 mg IM as a loading dose in some protocols). But a growing body of evidence suggests lower doses work just as well. A randomized, double-blind trial in the emergency department compared 10, 15, and 30 mg IV ketorolac for moderate to severe pain and found no significant differences in analgesic effect among the three doses.¹⁴ The kidney stone trial mentioned earlier came to the same conclusion for renal colic. This is important because higher doses carry more risk of side effects, particularly gastrointestinal bleeding and kidney problems. Many emergency physicians have moved toward using 15 mg or even 10 mg as their default dose, getting the same pain relief with less risk.

The Five-Day Rule

Toradol carries a strict time limit that sets it apart from most pain medications: it should not be used for more than five days in a row. This is not a soft guideline. The risk of serious adverse effects, particularly gastrointestinal bleeding, kidney damage, and cardiovascular problems, rises substantially with prolonged use or high doses.¹⁵ Elderly patients face even higher risk. The five-day ceiling applies regardless of the route: if you started with an injection in the hospital and switched to oral tablets at home, the clock started when you got the first injection. Some clinicians prefer to keep courses even shorter, at two to three days, especially in patients with any risk factors.

Gastrointestinal Risks

The most well-documented danger of Toradol is stomach and intestinal bleeding. All NSAIDs carry some GI risk, but ketorolac sits at the top of the list. A large epidemiological study found that ketorolac carried the highest risk of hospitalization for upper GI bleeding among all NSAIDs examined, with a risk roughly five times greater than other NSAIDs as a group. That elevated risk was present with both oral and intramuscular use and appeared even during the first week of treatment.¹⁶ A separate study in elderly patients had to be stopped early after an unexpectedly high rate of gastric and duodenal ulcers developed in the ketorolac group, with some patients developing multiple ulcers even after short-term use.¹⁷

This is the main reason for the five-day limit and why doctors are cautious about giving Toradol to anyone with a history of stomach ulcers, GI bleeding, or heavy alcohol use. If you are offered Toradol and have a history of stomach problems, make sure your provider knows.

Bleeding Risk After Surgery

Because ketorolac affects platelet function (how well your blood clots), there has been longstanding concern about whether it increases surgical bleeding. The evidence here is more reassuring than the GI data. A meta-analysis of 27 randomized controlled trials found that postoperative bleeding occurred in about 2.5% of patients receiving ketorolac and about 2.1% of those receiving a placebo or comparator, a difference that was not statistically significant.¹⁸ A broader evidence review reached the same conclusion, noting that while some earlier observational data had suggested a small increase in GI bleeding with ketorolac, the randomized trial evidence did not show a significant increase in operative-site bleeding.¹⁹

That said, case reports of serious bleeding events after even a single dose do exist. One documented case involved a patient who developed a life-threatening intra-abdominal bleed requiring emergency surgery after receiving just one dose of ketorolac on the sixth day after a prior operation.²⁰ Rare events like this do not outweigh the broader trial data, but they remind surgeons to weigh individual patient factors before writing the order.

Does It Slow Bone Healing?

Orthopedic surgeons have a particular concern with Toradol that other specialties do not share: whether it interferes with bones knitting back together. NSAIDs in general can inhibit the inflammatory signals that are part of the early bone-healing process, and some animal studies using high doses of ketorolac for four weeks or more showed delayed healing. The clinical picture, though, is more nuanced. A review of both the animal and human evidence found that short-term perioperative use of ketorolac did not increase the risk of delayed healing or nonunion in most orthopedic settings. The exception is spinal fusion surgery, where some clinical data has shown a dose-dependent increase in the risk of the fusion failing to solidify.²¹

Outside the spine, the data is reassuring. A study of ankle fracture patients who received perioperative ketorolac found a 94% clinical healing rate within 12 weeks and zero cases of nonunion in the entire cohort of 281 patients.²² The emerging consensus is that short courses of ketorolac around the time of surgery are likely fine for most fractures and joint procedures, but spine surgeons have reason to be more conservative.

Toradol in Professional Sports

Toradol has a long and somewhat controversial history in professional athletics, particularly in the NFL. For years, intramuscular ketorolac injections were a routine part of game day in professional football, given to players to manage musculoskeletal injuries and prevent postgame soreness. At the peak of this practice, over 93% of NFL teams reported using intramuscular ketorolac on game days. That rate dropped to about 48% by 2016. Collegiate football saw a similar decline, from 62% game-day use in 2008 down to 26% in 2016.²³

The decline was driven partly by updated recommendations from the NFL Physician Society, which issued a task force report laying out specific guardrails. The task force recommended that ketorolac should not be used prophylactically, meaning it should not be given before a game just to prevent pain that has not happened yet. It should only be given to players with a diagnosed injury, at the lowest effective dose, for no more than five days, and under the direct order of a team physician. Players with any history of GI bleeding, kidney problems, or NSAID-related complications should not receive it at all.²⁴ The concern was that widespread pregame injections could mask pain signals that exist to protect the body from further injury, while simultaneously exposing healthy athletes to the drug’s GI and renal risks unnecessarily.

The shift away from routine Toradol use in sports mirrors a broader trend in medicine: recognizing that a powerful drug should be reserved for situations where its benefits clearly outweigh its risks, rather than being handed out as a convenience.

Cardiovascular Safety

Many NSAIDs, particularly those used long-term, carry warnings about increased heart attack and stroke risk. Toradol is a bit of an outlier here, partly because its approved use is so short. A large study comparing parenteral ketorolac to opioid courses in hospitalized patients found that heart attacks occurred in about 0.2% of ketorolac courses versus about 0.4% of opioid courses. After adjusting for factors like age, sex, diabetes, and cardiovascular history, ketorolac was still associated with a lower risk of heart attack compared to opioids.²⁵ This does not mean ketorolac protects the heart; it may simply reflect the fact that ketorolac is used for only a few days at a time, while the cardiovascular risks that concern doctors with other NSAIDs tend to accumulate over weeks and months of use. Still, for the short-term window in which Toradol is appropriate, the cardiovascular signal looks relatively clean compared to the GI signal.